Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Measuring Atopic Eczema Control and Itch Intensity in Clinical Practice: A Consensus Statement From the Harmonising Outcome Measures for Eczema in Clinical Practice (HOME-CP) Initiative.
Leshem YA, Chalmers JR, Apfelbacher C, Katoh N, Gerbens LAA, Schmitt J, Spuls PI, Thomas KS, Howells L, Williams HC, Simpson EL; Harmonising Outcome Measures for Eczema (HOME) initiative. Leshem YA, et al. JAMA Dermatol. 2022 Dec 1;158(12):1429-1435. doi: 10.1001/jamadermatol.2022.4211. JAMA Dermatol. 2022. PMID: 36223090
Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysis from BREEZE-AD7.
Masuda K, Delozier AM, Kolodsick J, Buchanan A, Pink AE, Sun L, Wang Z, Stingeni L, Thac I D. Masuda K, et al. Among authors: delozier am. Eur J Dermatol. 2022 Apr 1;32(2):237-243. doi: 10.1684/ejd.2022.4242. Eur J Dermatol. 2022. PMID: 35866910 English.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, Ghislain PD, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K; BREEZE-AD4 study group. Bieber T, et al. Among authors: delozier am. Br J Dermatol. 2022 Sep;187(3):338-352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. Br J Dermatol. 2022. PMID: 35484697 Clinical Trial.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis.
Simpson EL, Bissonnette R, Paller AS, King B, Silverberg JI, Reich K, Thyssen JP, Doll H, Sun L, DeLozier AM, Nunes FP, Eichenfield LF. Simpson EL, et al. Among authors: delozier am. Br J Dermatol. 2022 Oct;187(4):531-538. doi: 10.1111/bjd.21615. Epub 2022 Aug 21. Br J Dermatol. 2022. PMID: 35442530 Free PMC article.
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
Rosmarin D, Fretzin S, Strowd L, Casillas M, DeLozier AM, Dawson Z, Chen S, Lu N, Thyssen JP. Rosmarin D, et al. Among authors: delozier am. J Cutan Med Surg. 2022 Jul-Aug;26(4):377-385. doi: 10.1177/12034754221088542. Epub 2022 Mar 31. J Cutan Med Surg. 2022. PMID: 35354410 Clinical Trial.
Stigma, Intrusiveness, and Distress in Parents of Children with a Disorder/Difference of Sex Development.
Traino KA, Roberts CM, Fisher RS, Delozier AM, Austin PF, Baskin LS, Chan YM, Cheng EY, Diamond DA, Fried AJ, Kropp B, Lakshmanan Y, Meyer SZ, Meyer T, Buchanan C, Palmer BW, Paradis A, Reyes KJ, Tishelman A, Williot P, Wolfe-Christensen C, Yerkes EB, Mullins LL, Wisniewski AB. Traino KA, et al. Among authors: delozier am. J Dev Behav Pediatr. 2022 Sep 1;43(7):e473-e482. doi: 10.1097/DBP.0000000000001077. Epub 2022 Mar 30. J Dev Behav Pediatr. 2022. PMID: 35353771 Free PMC article.
The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata.
Gelhorn HL, Cutts K, Edson-Heredia E, Wright P, Delozier A, Shapiro J, Senna M, Tosti A. Gelhorn HL, et al. Among authors: delozier a. Dermatol Ther (Heidelb). 2022 Apr;12(4):989-997. doi: 10.1007/s13555-022-00702-4. Epub 2022 Mar 29. Dermatol Ther (Heidelb). 2022. PMID: 35352323 Free PMC article.
64 results